Seeking Alpha
15 Jul 2026, 18:31 UTC · 1h ago
Compass Therapeutics: A 50% Price Cut Hiding A Regulatory Mispricing Opportunity
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Seeking Alpha
15 Jul 2026, 18:31 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
FDA rejection of tovecimig would risk a 50% dilution of shares and multi-year delays. — Significant equity dilution and loss of near-term catalyst represent severe downside risk for shareholders.
-0.80FDA approval of tovecimig could potentially double the company's stock price. — Positive regulatory approval for a lead asset acts as a primary valuation driver for small-cap biotech.
+0.70Overall Survival (OS) crossover contamination may complicate the FDA approval process for tovecimig. — Data quality issues create uncertainty and increase the probability of a regulatory setback.
-0.40Tovecimig demonstrated strong Progression-Free Survival (PFS) benefit in biliary tract cancer (BTC). — Strong clinical efficacy provides the fundamental basis for the drug's potential market success.
Continue reading
6 related stories
Top 1 mover · tap to explore
Which stocks this story touches
The company is rated as a Buy with upside potential despite uncertainties regarding FDA approval prospects.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Proactive Investors
37m ago
